Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors.
Yuko MakinoChihiro OeKazuya IwamaSatoshi SuzukiAkie NishiyamaKazuya HasegawaHaruka OkudaKazushige HirataMariko UenoKumi KawajiMina SasanoEmiko UsuiToshiaki HosakaYukako YabukiMikako ShirouzuMakoto KatsumiKazutaka MurayamaHironori HayashiEiichi N KodamaPublished in: Communications biology (2022)
Serine hydroxymethyltransferase (SHMT) produces 5,10-methylenetetrahydrofolate (CH 2 -THF) from tetrahydrofolate with serine to glycine conversion. SHMT is a potential drug target in parasites, viruses and cancer. (+)-SHIN-1 was developed as a human SHMT inhibitor for cancer therapy. However, the potential of SHMT as an antibacterial target is unknown. Here, we show that (+)-SHIN-1 bacteriostatically inhibits the growth of Enterococcus faecium at a 50% effective concentration of 10 -11 M and synergistically enhances the antibacterial activities of several nucleoside analogues. Our results, including crystal structure analysis, indicate that (+)-SHIN-1 binds tightly to E. faecium SHMT (efmSHMT). Two variable loops in SHMT are crucial for inhibitor binding, and serine binding to efmSHMT enhances the affinity of (+)-SHIN-1 by stabilising the loop structure of efmSHMT. The findings highlight the potency of SHMT as an antibacterial target and the possibility of developing SHMT inhibitors for treating bacterial, viral and parasitic infections and cancer.
Keyphrases
- papillary thyroid
- crystal structure
- silver nanoparticles
- cancer therapy
- protein kinase
- endothelial cells
- squamous cell
- sars cov
- human health
- emergency department
- transcription factor
- squamous cell carcinoma
- pseudomonas aeruginosa
- molecular docking
- drug induced
- room temperature
- staphylococcus aureus
- lymph node metastasis